Neuroendocrine gastro-entero-pancreatic tumors: ESMO clinical practice guidelines for diagnosis, treatment and follow-up

Annals of Oncology

Volumn 23, Issue SUPPL. 7, 2012, Pages

  Oberg K ^a   Knigge, U ^b   Kwekkeboom, D ^c   Perren, A ^d  

^a UPPSALA UNIVERSITY HOSPITAL   (Sweden)

^b Rigshospitalet   (Denmark)

^c ERASMUS MEDICAL CENTER   (Netherlands)

^d UNIVERSITY OF BERN   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; CAPECITABINE; CISPLATIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; ETOPOSIDE; EVEROLIMUS; FLUOROURACIL; LUTETIUM 177; OCTREOTIDE; PAZOPANIB; PLACEBO; SOMATOSTATIN DERIVATIVE; STREPTOZOCIN; SUNITINIB; TEMOZOLOMIDE; YTTRIUM 90;

ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER GRADING; CANCER RADIOTHERAPY; CANCER STAGING; CARCINOID; CHEMOEMBOLIZATION; CLINICAL EVALUATION; COMPUTER ASSISTED TOMOGRAPHY; CYTOREDUCTIVE SURGERY; DISEASE ASSOCIATION; DISTANT METASTASIS; DRUG EFFICACY; DRUG WITHDRAWAL; FOLLOW UP; HISTOPATHOLOGY; HUMAN; INCIDENCE; LIVER METASTASIS; LYMPH NODE METASTASIS; MOLECULARLY TARGETED THERAPY; NEUROENDOCRINE TUMOR; NUCLEAR MAGNETIC RESONANCE IMAGING; OUTCOME ASSESSMENT; PANCREAS TUMOR; PRIORITY JOURNAL; RISK ASSESSMENT; SMALL INTESTINE TUMOR; STOMACH TUMOR; SURVIVAL RATE; TREATMENT RESPONSE; TUMOR LOCALIZATION; TUMOR VOLUME;

ANTINEOPLASTIC AGENTS, HORMONAL; COMBINED MODALITY THERAPY; HUMANS; INTESTINAL NEOPLASMS; NEOPLASM STAGING; NEOPLASMS, HORMONE-DEPENDENT; NEUROENDOCRINE TUMORS; PANCREATIC NEOPLASMS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RISK ASSESSMENT; STOMACH NEOPLASMS; TREATMENT OUTCOME;

EID: 84866595521     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mds295     Document Type: Article

References (31)

1. Yao JC, Hassan M, Phan A et al. One hundred years after "carcinoid": epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States. J Clin Oncol 2008; 26: 3063-3072.
2. Rindi G, Arnold R, Bosman FT et al. Nomenclature and classification of neuroendocrine neoplasms of the digestive system. In Bosman FT, Hruban RH, Theise ND (eds), WHO Classification of Tumours of the Digestive System. Lyon: IARC 2010; 13-14.
3. Pape UF, Jann H, Muller-Nordhorn J et al. Prognostic relevance of a novel TNM classification system for upper gastroenteropancreatic neuroendocrine tumors. Cancer 2008; 113: 256-265.
4. Rockall AG, Reznek RH. Imaging of neuroendocrine tumours (CT/MR/US). Best Pract Res Clin Endocrinol Metab 2007; 21: 43-68.
5. Sundin A, Vullierme MP, Kaltsas G et al. ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: radiological examinations. Neuroendocrinology 2009; 90: 167-183.
6. Koopmans KP, Neels OC, Kema IP et al. Improved staging of patients with carcinoid and islet cell tumors with 18F-dihydroxy-phenyl-alanine and 11C-5-hydroxy-tryptophan positron emission tomography. J Clin Oncol 2008; 26: 1489-1495.
7. Binderup T, Knigge U, Loft A et al. 18F-fluorodeoxyglucose positron emission tomography predicts survival of patients with neuroendocrine tumors. Clin Cancer Res 2010; 16: 978-985.
8. Eriksson B, Oberg K, Stridsberg M. Tumor markers in neuroendocrine tumors. Digestion 2000; 62(Suppl 1): 33-38.
9. Ekeblad S, Skogseid B, Dunder K et al. Prognostic factors and survival in 324 patients with pancreatic endocrine tumor treated at a single institution. Clin Cancer Res 2008; 14: 7798-7803.
10. Ahmed A, Turner G, King B et al. Midgut neuroendocrine tumours with liver metastases: results of the UKINETS study. Endocr Relat Cancer 2009; 16: 885-894.
11. Halfdanarson TR, Rabe KG, Rubin J et al. Pancreatic neuroendocrine tumors (PNETs): incidence, prognosis and recent trend toward improved survival. Ann Oncol 2008; 19: 1727-1733.
12. Townsend A, Price T, Yeend S et al. Metastatic carcinoid tumor: changing patterns of care over two decades. J Clin Gastroenterol 2010; 44: 195-199.
13. Akerstrom G, Hellman P. Surgery on neuroendocrine tumours. Best Pract Res Clin Endocrinol Metab 2007; 21: 87-109.
14. Kianmanesh R, O'Toole D, Sauvanet A et al. Surgical treatment of gastric, enteric pancreatic endocrine tumors. Part 2. treatment of hepatic metastases. J Chir (Paris) 2005; 142: 208-219.
15. Sarmiento JM, Que FG. Hepatic surgery for metastases from neuroendocrine tumors. Surg Oncol Clin N Am 2003; 12: 231-242.
16. Eriksson J, Stalberg P, Nilsson A et al. Surgery and radiofrequency ablation for treatment of liver metastases from midgut and foregut carcinoids and endocrine pancreatic tumors. World J Surg 2008; 32: 930-938.
17. Mazzaglia PJ, Berber E, Milas M et al. Laparoscopic radiofrequency ablation of neuroendocrine liver metastases: a 10-year experience evaluating predictors of survival. Surgery 2007; 142: 10-19.
18. Vogl TJ, Naguib NN, Zangos S et al. Liver metastases of neuroendocrine carcinomas: interventional treatment via transarterial embolization, chemoembolization and thermal ablation. Eur J Radiol 2009; 72: 517-528.
19. Kennedy AS, Dezarn WA, McNeillie P et al. Radioembolization for unresectable neuroendocrine hepatic metastases using resin 90Y-microspheres: early results in 148 patients. Am J Clin Oncol 2008; 31: 271-279.
20. Oberg K, Kvols L, Caplin M et al. Consensus report on the use of somatostatin analogs for the management of neuroendocrine tumors of the gastroenteropancreatic system. Ann Oncol 2004; 15: 966-973.
21. Modlin IM, Pavel M, Kidd M et al. Review article: somatostatin analogues in the treatment of gastroenteropancreatic neuroendocrine (carcinoid) tumours. Aliment Pharmacol Ther 2010; 31: 169-188.
22. Oberg K. Interferon in the management of neuroendocrine GEP-tumors: a review. Digestion 2000; 62(Suppl 1): 92-97.
23. Rinke A, Muller HH, Schade-Brittinger C et al. Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID Study Group. J Clin Oncol 2009; 27: 4656-4663.
24. Pavel ME, Hainsworth JD, Baudin E et al. Everolimus plus octreotide long-acting repeatable for the treatment of advanced neuroendocrine tumours associated with carcinoid syndrome (RADIANT-2): a randomised, placebo-controlled, phase 3 study. Lancet 2011; 378: 2005-2012.
25. Yao JC, Shah MH, Ito T et al. Everolimus for advanced pancreatic neuroendocrine tumors. N Engl J Med 2011; 364: 514-523.
26. Raymond E, Dahan L, Raoul JL et al. Sunitinib malate for the treatment of pancreatic neuroendocrine tumors. N Engl J Med 2011; 364: 501-513.
27. Turner NC, Strauss SJ, Sarker D et al. Chemotherapy with 5-fluorouracil, cisplatin and streptozocin for neuroendocrine tumours. Br J Cancer 2010; 102: 1106-1112.
28. Strosberg JR, Fine RL, Choi J et al. First-line chemotherapy with capecitabine and temozolomide in patients with metastatic pancreatic endocrine carcinomas. Cancer 2011; 117: 268-275.
29. Welin S, Sorbye H, Sebjornsen S et al. Clinical effect of temozolomide-based chemotherapy in poorly differentiated endocrine carcinoma after progression on first-line chemotherapy. Cancer 2011; 117: 4617-4622.
30. Sorbye H, Welin S, Langer S et al. NNTG: Nordic Neuroendocrine Tumor Group. Predictive and prognostic factors for treatment and survival in 305 patients with advanced gastrointestinal poorly differentiated neuroendocrine carcinoma: The NORDIC NEC study. ASCO 2012: abst #4015.
31. Kwekkeboom DJ, de Herder WW, Kam BL et al. Treatment with the radiolabeled somatostatin analog [177 Lu-DOTA 0, Tyr3]octreotate: toxicity, efficacy, and survival. J Clin Oncol 2008; 26: 2124-2130.